CanSino Biologics Inc (CJH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CanSino Biologics Inc (CJH) has a cash flow conversion efficiency ratio of -0.066x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-392.00 Million ≈ $-458.29 Million USD) by net assets (€5.97 Billion ≈ $6.98 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CJH stock market capitalisation for the company's overall valuation and market capitalisation.
CanSino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how CanSino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CanSino Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CanSino Biologics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of CanSino Biologics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinopec Shanghai Petrochemical Company Limited
F:SGJH
|
-0.008x |
|
Good Finance Securities Co Ltd
TWO:6021
|
-0.047x |
|
Oriental Kopi Holdings Berhad
KLSE:0338
|
0.052x |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
-0.013x |
|
ARTRYA Ltd
AU:AYA
|
-0.122x |
|
Strata Critical Medical, Inc.
NASDAQ:SRTA
|
0.012x |
|
Select Harvests Ltd
AU:SHV
|
0.005x |
|
Consolidated Water Co. Ltd
F:CW2
|
0.026x |
Annual Cash Flow Conversion Efficiency for CanSino Biologics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2025. View CanSino Biologics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.95 Billion ≈ $5.79 Billion |
€77.86 Million ≈ $91.02 Million |
0.016x | +145.72% |
| 2024-12-31 | €4.91 Billion ≈ $5.74 Billion |
€-168.79 Million ≈ $-197.33 Million |
-0.034x | +80.16% |
| 2023-12-31 | €5.29 Billion ≈ $6.18 Billion |
€-916.25 Million ≈ $-1.07 Billion |
-0.173x | +32.19% |
| 2022-12-31 | €7.25 Billion ≈ $8.47 Billion |
€-1.85 Billion ≈ $-2.16 Billion |
-0.256x | -206.55% |
| 2021-12-31 | €8.55 Billion ≈ $9.99 Billion |
€2.05 Billion ≈ $2.40 Billion |
0.240x | +516.06% |
| 2020-12-31 | €6.07 Billion ≈ $7.10 Billion |
€-349.93 Million ≈ $-409.11 Million |
-0.058x | +45.05% |
| 2019-12-31 | €1.47 Billion ≈ $1.72 Billion |
€-154.25 Million ≈ $-180.33 Million |
-0.105x | +57.38% |
| 2018-12-31 | €502.32 Million ≈ $587.26 Million |
€-123.64 Million ≈ $-144.55 Million |
-0.246x | -165.51% |
| 2017-12-31 | €607.33 Million ≈ $710.03 Million |
€-56.30 Million ≈ $-65.82 Million |
-0.093x | +42.17% |
| 2016-12-31 | €214.47 Million ≈ $250.74 Million |
€-34.38 Million ≈ $-40.20 Million |
-0.160x | -- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical … Read more